Palbociclib Dose Modification Guidelines

Monitoring and Dose Adjustment

The American Society of Clinical Oncology recommends monitoring complete blood counts on Day 14 of the first two 28-day cycles and at the start of each subsequent cycle, managing neutropenia through dose delays and reductions 1, 2, 3, 4
For Grade 3-4 Neutropenia (ANC <1000/mm³), hold palbociclib until ANC ≥1500/mm³, as recommended by the National Comprehensive Cancer Network 1, 2, 3, 4
After the first occurrence of Grade 3-4 neutropenia, resume palbociclib at the starting dose (125 mg) once ANC ≥1500/mm³, according to the Journal of Clinical Oncology 1, 2, 3
In cases of recurrent Grade 3-4 neutropenia, hold the drug until ANC ≥1500/mm³ and resume at a reduced dose (100 mg, then 75 mg if needed), as suggested by the Journal of Clinical Oncology 1, 2, 3, 5

Growth factors can be used in combination with palbociclib for patients with resistant neutropenia, as recommended by the National Comprehensive Cancer Network 6, 7
The incidence of febrile neutropenia is low (<2% in clinical trials), and when it occurs, manage with standard supportive care, according to the Journal of Clinical Oncology 6, 5, 7

Grade 3-4 neutropenia occurs in 54-62% of patients, and leukopenia occurs in 19-25% of patients, as reported by the National Comprehensive Cancer Network and the Journal of Clinical Oncology 4, 6, 7

The National Comprehensive Cancer Network advises against delaying monitoring, as missing Day 14 CBC checks during the first two cycles can result in undetected severe neutropenia 1, 2
The Journal of Clinical Oncology recommends reducing the dose for recurrent Grade 3-4 neutropenia events, rather than resuming at the full dose 1, 2, 3

The American Society of Clinical Oncology guidelines recommend monitoring blood counts on day 14 of the first two 28-day cycles and at the start of each subsequent cycle, with neutropenia managed through dose delays and reductions 8, 9

Complete blood count (CBC) should be performed at cycle start (Day 1), on Day 14 (mid-cycle), and at the start of the next cycle (Day 28) for the first two cycles 8, 9
For subsequent cycles (Cycle 3 onwards), CBC should be performed at the start of each 28-day cycle only, with mid-cycle monitoring (Day 14) discontinued if no significant neutropenia has occurred 8, 10, 11

Palbociclib is administered 125 mg once daily for 21 consecutive days, followed by 7 days off (28-day cycle) 8, 9
Dose delays and reductions (from 125 mg to 100 mg, then to 75 mg if needed) should be implemented for significant neutropenia 8, 9